Long-term storage of lipid-like nanoparticles for mRNA delivery

Zhao, Pengxuan; Hou, Xucheng; Yan, Jiajie; Du, Shi; Xue, Yonger; Li, Wenqing; Xiang, Guangya; Dong, Yizhou

doi:10.1016/j.bioactmat.2020.03.001

Cited by 147 publications

(162 citation statements)

References 33 publications

Supporting

Mentioning

149

Contrasting

Order By: Relevance

“…Most RNA LNPs made in the laboratory are stable at 4 °C for several days, but then exhibit size increases and a gradual loss of bioactivity, such as luciferase expression [ 116 ]. A size increase over time from LNP aggregation has been commonly observed in previous siRNA LNP formulations [ 117 ].…”

Section: Mrna Lipid Nanoparticles In the Current Sars-cov-2 Clinicmentioning

confidence: 99%

Nanomaterial Delivery Systems for mRNA Vaccines

et al. 2021

View full text Add to dashboard Cite

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.

show abstract

Section: Mrna Lipid Nanoparticles In the Current Sars-cov-2 Clinicmentioning

confidence: 99%

Nanomaterial Delivery Systems for mRNA Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…published their findings on the performance of freeze-dried LNP-mRNA (encoding for luciferase) with different lyoprotectants compared to fresh LNPs. 27 They examined both in vitro and in vivo mRNA expression (single-dose, i.v. injection) in mice.…”

Section: Description Of the Mrna Covid-19 Vaccines Being Tested In Thmentioning

confidence: 99%

Addressing the Cold Reality of mRNA Vaccine Stability

Crommelin

Anchordoquy

Volkin

et al. 2021

Journal of Pharmaceutical Sciences

356

297

View full text Add to dashboard Cite

“…Lipids or lipid-like materials (lipidoids) are able to form various vesicles, e.g., LNP, liposome, lipid emulsion, lipid implant, with nuclei acids [ 3 , [7] , [8] , [9] , [10] , [11] ]. A series of cationic lipids and ionizable lipids such as 1,2-dioleoyloxy-3-trimethylammonium propane chloride (DOTAP), N-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammo- nium chloride (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dilinoleylmethyl-4-dimethylaminobutyrate (Dlin-MC3-DMA) have been investigated for siRNA or mRNA delivery [ 5 , 10 , [12] , [13] , [14] , [15] , [16] , [17] ]. Ionizable LNP (iLNP) is more clinically advanced than other deliver systems in the context of RNA delivery.…”

Section: Introductionmentioning

confidence: 99%

Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle

Yang

Wang

et al. 2020

Bioactive Materials

View full text Add to dashboard Cite

mRNA is a novel class of therapeutic modality that holds great promise in vaccination, protein replacement therapy, cancer immunotherapy, immune cell engineering etc. However, optimization of mRNA molecules and efficient in vivo delivery are quite important but challenging for its broad application. Here we present an ionizable lipid nanoparticle (iLNP) based on iBL0713 lipid for in vitro and in vivo expression of desired proteins using codon-optimized mRNAs. mRNAs encoding luciferase or erythropoietin (EPO) were prepared by in vitro transcription and formulated with proposed iLNP, to form iLP171/mRNA formulations. It was revealed that both luciferase and EPO proteins were successfully expressed by human hepatocellular carcinoma cells and hepatocytes. The maximum amount of protein expression was found at 6 h post-administration. The expression efficiency of EPO with codon-optimized mRNA was significantly higher than that of unoptimized mRNA. Moreover, no toxicity or immunogenicity was observed for these mRNA formulations. Therefore, our study provides a useful and promising platform for mRNA therapeutic development.

show abstract

Long-term storage of lipid-like nanoparticles for mRNA delivery

Cited by 147 publications

References 33 publications

Nanomaterial Delivery Systems for mRNA Vaccines

Nanomaterial Delivery Systems for mRNA Vaccines

Addressing the Cold Reality of mRNA Vaccine Stability

Efficient hepatic delivery and protein expression enabled by optimized mRNA and ionizable lipid nanoparticle

Contact Info

Product

Resources

About